How did Riverwater explain the stock’s decline?

LeMaitre Vascular was among the stocks highlighted in Riverwater Partners’ second-quarter 2026 investor letter. The firm’s small-cap-focused strategy lagged the Russell 2000 index, which rose over the quarter on a strong appetite for risk; fund managers linked that backdrop to flows into more speculative stocks.

According to Riverwater Partners, the quarter was shaped by accelerating artificial intelligence investment, disruptions in energy markets and renewed interest in high-beta stocks. That environment pressured the performance of its quality-focused approach and overweight to healthcare. The fund said LeMaitre Vascular shares fell about 12% in the second quarter, but its view of the company’s niche market leadership, pricing power and operational stability remained unchanged.

Which areas benefited from the market rotation?

In the investor letter, the firm said even profitable small-cap healthcare stocks were sold off, while buying intensified in more speculative companies. Riverwater Partners said its stock picks made positive contributions in energy, materials and financials, while healthcare and consumer discretionary names were weaker.

  • Artificial intelligence investment accelerated
  • Rising volatility in energy markets
  • Renewed risk appetite for high-beta stocks

What do the latest numbers say about LeMaitre Vascular?

As of the Aug. 31, 2026 close, the stock was trading at $80.28. Data show LMAT has lost 24.11% over the past month and is down 15.52% over the past 52 weeks. The company’s market value was calculated at $1.84 billion, while its 52-week trading range was between $78.27 and $118.01.

Decline in hedge fund interest stood out

LeMaitre Vascular was not among the 40 most popular stocks held by hedge funds. By the end of the second quarter, the company was in the portfolios of 22 hedge funds, down from 26 in the previous quarter. The drop suggests institutional interest in the stock has weakened in the short term.

Market impact and what to watch

Riverwater Partners said LeMaitre Vascular’s pullback was driven more by market sentiment and sector rotation than by the company’s fundamentals. It said a renewed influx of capital into small-cap healthcare companies will be critical to easing pressure on the stock.

Going forward, investors will be watching whether the speculative rally continues and whether money rotates back into quality-focused names. For LMAT, broader risk appetite toward small-cap healthcare stocks is likely to remain as important as the share price move itself.